Most glioblastoma recurrences clustered within 10 mm of the original GTV
In 201 recurrent glioblastomas, 80% required no more than 10.4 mm expansion to encompass 80% of recurrence volume.
Latest
KROG 19-09 reveals major dose variation within intended breast nodal treatment groups
Substantial physician-dependent dose variation meant treatment-group assignment did not consistently reflect the dose actually delivered to regional nodes.
Oligometastatic survivorship is outgrowing traditional oncology follow-up models
Longer survival after metastasis-directed therapy is creating unmet physical, psychological and functional needs that conventional surveillance pathways may not adequately address.
VMAT lattice radiotherapy produced 65% median shrinkage in bulky hepatocellular carcinoma
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Reusable 3D-printed devices shaped small proton fields for under $1 in filament
Hollow 3D-printed proton collimators and compensators were produced within 45 minutes and accurately shaped small experimental proton fields.
SRT did not improve survival over whole-brain radiotherapy after matching in SCLC
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
Updated ASTRO guideline expands radiation therapy across pancreatic cancer settings
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
VMAT lattice radiotherapy on standard linacs provided early palliation in bulky tumors
In eight bulky tumor sites, flattening-filter VMAT lattice radiotherapy produced 75% symptom relief with no grade 3 or higher acute toxicity.
Brainlab reference beam model enabled one-day SRS commissioning with accurate Monte Carlo calculations
Brainlab Elements commissioning was completed in one day, while Monte Carlo generally agreed with end-to-end measurements within 3%.
Time-series CT radiomics predicted rib fracture after lung SBRT with 0.79 validation AUC
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
OCTAVIUS 4D achieved 98.3% gamma passing for MR-LINAC SBRT QA
Across 40 Unity SBRT plans, OCTAVIUS 4D achieved 98.3% mean local gamma passing with sub-degree angular agreement.
ESTRO review supports selective CNS reirradiation but highlights cumulative-dose limits
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
AI biomarker substantially reduced planned ADT use in intermediate-risk prostate cancer
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.
Short-course radiotherapy may be a stronger immunotherapy partner in rectal cancer
Recent trials report 40–61% pathologic complete response with short-course radiotherapy plus immunotherapy, but mature comparative outcomes remain unavailable.